This page is an English translation of the Korean original. If there is any discrepancy, the Korean version prevails.

Tuberous sclerosis결절성 경화증

📋 Contents and key points
ItemDetails
A. Classification codesICD-10: Q85.1 / Special Copayment Reduction: V204 / Re-certification cycle: 5 years
B. SynonymsEpiloia, Bourneville disease
C. Adult onsetPresents with infantile seizures; renal angiomyolipoma and pulmonary lymphangioleiomyomatosis progress in adulthood
1. HistoryDescribed by Bourneville in 1880; history of identification of TSC1/TSC2
2. EpidemiologyBirth frequency 1/5,800–6,000; worldwide prevalent population estimated at about 1 million
3. Etiology and geneticsTSC1 (9q34, hamartin)/TSC2 (16p13.3, tuberin); mTORC1 hyperactivation
4. PathophysiologyLoss of function of the TSC1/TSC2 complex → Rheb-GTP accumulation → mTORC1 upregulation
5. Clinical featuresCortical tubers, infantile spasms, facial angiofibromas, renal angiomyolipoma, LAM
6. Diagnostic criteria2012 International TSC Consensus diagnostic criteria; distinction between definite and possible diagnosis
7. Differential diagnosisNF1, Peutz-Jeghers syndrome, sporadic LAM, renal AML
8. Laboratory and imaging findingsBrain, abdominal, and chest MRI, EEG, fundus examination, molecular genetic testing
9. TreatmentEverolimus/sirolimus (mTOR inhibitors), ACTH, vincristine, surgery
10. ComplicationsDrug-resistant epilepsy, intellectual decline, renal failure, spontaneous pneumothorax, renal AML hemorrhage
11. PrognosisExtent of brain involvement and seizure control determine prognosis; improvement with mTOR therapy
12. PreventionGenetic counseling, PGT-M, periodic multi-organ surveillance, early anticonvulsant treatment
13. ReferencesNorthrup H et al. (2013) Updated International TSC Consensus Conference and 9 other papers

1. History

The academic history of tuberous sclerosis complex (TSC) began in 1880, when the French neurologist Désiré-Magloire Bourneville first described nodular lesions in the cerebral cortex. He named these brain nodules 'sclérose tubéreuse' (tuberous sclerosis), which later became the name of the disease. He observed patients who had seizures, intellectual decline, and skin lesions together and was the first to present this as a single clinical entity.

Systematic description of the skin findings was made in 1890 when John James Pringle described facial angiofibromas (adenoma sebaceum). These skin findings were for a time wrongly called sebaceous adenomas, but were later confirmed to be angiofibromas. In the early 20th century, Heinrich Vogt in 1908 presented epilepsy, intellectual decline, and facial angiofibromas as the three major symptoms of tuberous sclerosis (Vogt triad), and this classification served as the diagnostic standard for decades.

With the advance of molecular genetics, the TSC2 gene was identified on chromosome 16p13.3 by Haines et al. in 1993, and its product, tuberin, was shown to be a tumor suppressor protein with a GTPase-activating protein domain. The TSC1 gene was cloned on chromosome 9q34 by van Slegtenhorst et al. in 1997, and it was subsequently shown that its product, hamartin, forms a complex with tuberin to regulate the mTOR pathway. After 2003 it was established that the mTOR signaling pathway is central to the pathogenesis of TSC, which led to the clinical application of mTOR inhibitors such as everolimus, a rapamycin derivative. TSC is now a model disease for research on mTOR-related rare diseases.

2. Epidemiology

The birth frequency of tuberous sclerosis is estimated at about 1/5,800–6,000, and the worldwide prevalent population is estimated at about 1 million. There is no difference in incidence by sex or ethnicity. In Korea it is registered and managed under the Special Copayment Reduction code V204, and the actual number of prevalent patients is expected to include mild and undiagnosed cases in addition to registered patients.

Regarding the distribution of TSC1 and TSC2 mutations, TSC2 mutations are more common, accounting for about 65–70% of the total, TSC1 mutations for about 15–20%, and in the remaining 15–20% no mutation is identified by standard testing. Patients with TSC1 mutations generally have a milder phenotype than those with TSC2 mutations. The proportion of de novo mutations is very high at about 65–70% of the total, which means that a child can develop the disease newly even when the parents are normal.

The neurological symptoms of tuberous sclerosis (especially infantile spasms) often appear between 3 and 9 months of age, allowing early diagnosis, but when symptoms are mild, diagnosis may be delayed until adulthood.

3. Etiology and genetics

The TSC1 gene is located on chromosome 9q34.13 and consists of 23 exons, and its protein product hamartin consists of 1,164 amino acids (130 kDa). The TSC2 gene is located on chromosome 16p13.3 and consists of 42 exons, and its product tuberin is 1,807 amino acids (200 kDa). Hamartin and tuberin form a heterodimer complex in the cytoplasm, and this TSC1-TSC2 complex functions as a GAP (GTPase-activating protein) for the small GTPase Rheb (Ras homolog enriched in brain).

When TSC complex function is lost owing to a TSC1 or TSC2 mutation, Rheb is maintained in its GTP-bound active form and continuously activates mTORC1 (mechanistic target of rapamycin complex 1). Activated mTORC1 promotes protein synthesis, cell growth, and cell proliferation through phosphorylation of S6K1 and 4E-BP1, and suppresses autophagy, inducing the growth of hamartomatous lesions.

The mode of inheritance is autosomal dominant, with nearly complete penetrance. Phenotypic diversity is large even within the same family (variable expressivity), and somatic mosaicism is found in about 10–15%. Patients with mosaicism show milder symptoms, and caution is needed in genetic counseling.

4. Pathophysiology

The core pathophysiology of tuberous sclerosis is constitutive activation of the mTORC1 signaling pathway. Normally, the TSC1-TSC2 complex precisely regulates mTORC1 activity by integrating various upstream signals such as nutrient signals, growth factor signals (PI3K-AKT), and energy status (AMPK). When TSC complex function is lost, mTORC1 is constitutively active, resulting in ① promotion of ribosome biogenesis and mRNA translation through S6 kinase, ② increased cap-dependent translation through 4E-BP1 phosphorylation, ③ reduced lysosomal function through TFEB suppression, and ④ increased angiogenesis through HIF-1α stabilization. In addition, mTORC1 activation suppresses PI3K-AKT signaling by negative feedback through feedback inhibition of IRS-1, so AKT reactivation may occur with mTOR inhibitor monotherapy.

Brain lesions (cortical tubers, subependymal nodules, giant cell astrocytomas) are formed by hyperproliferation of ectopic neurons and abnormally differentiated giant cells. Cortical tubers are focal cortical dysplasia that serve as the structural basis of neuronal hyperexcitability and are directly linked to the development of epilepsy. Skin angiofibromas are hamartomatous lesions with vascular proliferation and fibrosis, and renal angiomyolipomas are hamartomas composed of abnormal smooth muscle cells, blood vessels, and adipocytes. Pulmonary lymphangioleiomyomatosis (LAM) is a lesion in which smooth muscle-like cells with TSC2 mutations infiltrate the lung parenchyma by hematogenous and lymphatic spread.

5. Clinical features

Neurologic findings

Cortical tubers are the most characteristic brain lesions of TSC and are seen on MRI in 80–90% of patients. The number and location of tubers are associated with the development of epilepsy and cognitive impairment. Subependymal nodules (SEN) are calcified nodules around the ventricular wall that are well seen on CT and are observed in more than 80% of adults. Subependymal giant cell astrocytoma (SEGA) is located at the foramen of Monro and, as it grows, obstructs cerebrospinal fluid flow and causes hydrocephalus.

Epilepsy occurs in 80–90% of TSC patients, and infantile spasms (West syndrome) are the most common presentation. Most progress to drug-resistant epilepsy, and ACTH or vigabatrin is used as first-line treatment for infantile spasms. TSC-associated neuropsychiatric disorders (TAND) include autism spectrum disorder, intellectual decline, ADHD, anxiety disorders, and sleep disorders, and about 90% of patients have one or more TAND symptoms.

Skin findings

Hypomelanotic macules (ash-leaf spots) are the earliest finding, present from birth, and are well revealed on Wood's lamp examination. Facial angiofibromas are red papules that appear from about 4–6 years of age along the nasolabial folds. Forehead fibrous plaques, ungual fibromas (Koenen tumors), and shagreen patches are also diagnostically important.

Renal findings

Renal angiomyolipoma (AML) occurs in 70–80% of TSC patients and is multiple and bilateral. The risk of spontaneous hemorrhage (Wunderlich syndrome) increases when the diameter is 3 cm or more. Renal cysts and renal cell carcinoma can also occur.

Pulmonary findings

Lymphangioleiomyomatosis (LAM) is confirmed by CT in 30–40% of female TSC patients (fewer than half are symptomatic) and causes progressive airflow limitation, spontaneous pneumothorax, and chylothorax. Multifocal micronodular pneumocyte hyperplasia (MMPH) is also one of the pulmonary findings.

6. Diagnostic criteria

The 2012 International TSC Consensus diagnostic criteria (Northrup & Krueger) consist of 11 major criteria and 6 minor criteria. The major criteria include ① hypomelanotic macules (≥3, ≥5 mm), ② angiofibromas (≥3) or forehead fibrous plaque, ③ ungual fibromas (≥2), ④ shagreen patch, ⑤ retinal hamartoma, ⑥ cortical dysplasia (including cortical tubers), ⑦ subependymal nodules, ⑧ SEGA, ⑨ cardiac rhabdomyoma, ⑩ LAM, and ⑪ renal angiomyolipoma (≥2).

A definite diagnosis is made with 2 or more major criteria, or 1 major criterion + 2 or more minor criteria, or when a pathogenic TSC1/TSC2 variant is identified by molecular genetics. A possible diagnosis is made with 1 major criterion or 2 or more minor criteria. The co-occurrence of LAM and renal AML (excluding cases without other features) is counted as a single criterion only.

Molecular genetic testing is needed when the clinical diagnosis is uncertain, for genetic counseling, and for preimplantation genetic diagnosis. When a TSC1/TSC2 pathogenic variant is identified on NGS-based testing, a definite diagnosis is established regardless of clinical criteria.

7. Differential diagnosis

Neurofibromatosis type 1 (NF1): Differentiation of café-au-lait spots from hypomelanotic macules is needed. NF1 is characterized by café-au-lait spots (brown), whereas the hypomelanotic macules of TSC are light in color.

Sporadic lymphangioleiomyomatosis (sporadic LAM): When only LAM appears without TSC, it is differentiated by molecular genetic testing and multi-organ evaluation.

Focal cortical dysplasia (FCD): It may resemble cortical tubers on MRI, but if multiple, bilateral findings and skin and renal findings are absent, FCD is considered.

Subependymal giant cell astrocytoma (SEGA) vs. subependymal nodule: A growing ventricular wall lesion is regarded as SEGA, and an mTOR inhibitor or surgery is considered.

Renal angiomyolipoma (solitary): Because solitary renal AML also occurs sporadically apart from TSC, the presence of multi-organ lesions is checked.

8. Laboratory and imaging findings

Brain MRI: Cortical tubers (T2/FLAIR hyperintense, T1 hyperintense), subependymal nodules (calcified, T1 hyperintense), and SEGA (contrast enhancement) are evaluated. Diffusion-weighted imaging (DWI) and magnetic resonance spectroscopy (MRS) are used adjunctively to define the nature of brain lesions.

Abdominal MRI/ultrasound: The size, number, and fat components of renal AML are determined. When AML contains fatty low-attenuation components, MRI is superior to CT. It is also useful for differentiating renal cysts.

Chest HRCT: Performed to diagnose LAM. Multiple thin-walled cysts distributed uniformly in both lungs are characteristic. When these findings are present with TSC or serum VEGF-D ≥800 pg/mL, LAM can be diagnosed without a tissue biopsy.

Echocardiography: Cardiac rhabdomyoma is identified in infancy. Most regress spontaneously, but treatment is needed if there is outflow tract obstruction.

Electroencephalography (EEG): Essential for classifying seizure types and selecting anticonvulsants. The characteristic hypsarrhythmia pattern is identified in infantile spasms.

Fundus examination: Retinal hamartoma is identified.

Molecular genetic testing: NGS-based TSC1/TSC2 variant analysis; MLPA to detect large deletions/duplications.

9. Treatment

mTOR inhibitors are central to TSC treatment. Everolimus is a treatment approved by the FDA and the Ministry of Food and Drug Safety (MFDS), with indications for ① SEGA (age 2 or older), ② progressive renal AML, and ③ TSC-associated focal seizures (drug-resistant). In the EXIST-1 trial, the response rate for everolimus, defined as a reduction in SEGA volume of 35% or more, was 35%, and in the EXIST-2 trial the renal AML response rate was 42%. In the EXIST-3 trial, the seizure frequency reduction response rate in TSC-associated epilepsy reached 40%. Sirolimus is FDA-approved for the treatment of LAM and can be used in place of everolimus in TSC-associated LAM as well.

For infantile spasms, vigabatrin is particularly effective in TSC-associated infantile spasms (response rate 50–70%), but it has the side effect of visual field abnormalities, so regular visual field testing is needed. ACTH is also a first-line treatment option. For drug-resistant epilepsy, the ketogenic diet, vagus nerve stimulation, and epilepsy surgery (cortical tuber resection) are considered.

When renal AML hemorrhage occurs, selective arterial embolization is the first-line hemostatic treatment. If the size is reduced after everolimus pretreatment, surgery that minimizes unnecessary loss of renal tissue becomes possible. SEGA surgery is performed urgently when hydrocephalus develops.

Topical rapamycin ointment (sirolimus cream) has been reported to be effective for skin angiofibromas, and laser treatment (PDL, CO₂ laser) is also used for cosmetic purposes.

10. Complications

Drug-resistant epilepsy occurs in about 60–70% of TSC patients, and repeated seizures adversely affect brain development, increasing the risk of cognitive decline and autism spectrum disorder. Early seizure suppression is directly linked to neurodevelopmental prognosis.

Intellectual decline appears to varying degrees in about 44–65% of patients, and severe intellectual decline is related to the number of cortical tubers and the age at onset of early epilepsy.

Renal failure arises from replacement of normal renal parenchyma by bilateral multiple AMLs or from renal function impairment due to repeated hemorrhage. It is one of the main causes of death in TSC patients.

Spontaneous pneumothorax may appear as the first symptom in LAM patients, and because the recurrence rate is high, pleurodesis or pleurectomy is considered.

Hydrocephalus due to SEGA is a relatively rare complication but may require emergency surgery.

Cardiac rhabdomyomas are detected in the fetal period or infancy, and arrhythmia or heart failure due to outflow tract obstruction rarely occurs. Most regress spontaneously.

11. Prognosis

The prognosis of TSC is most affected by the extent of nervous system involvement and whether epilepsy is controlled. Patients with only mild skin findings and no epilepsy can expect an almost normal lifespan. In contrast, in patients who develop infantile spasms and progress to drug-resistant epilepsy, intellectual decline, autism spectrum disorder, and behavioral disorders overlap, and the reduction in quality of life is severe.

The main causes of TSC-related death are renal AML hemorrhage, renal failure, brain tumor (SEGA), and status epilepticus, and when LAM has progressed, respiratory failure is also an important cause of death. Since the introduction of mTOR inhibitors, treatment effects on SEGA, renal AML, LAM, and epilepsy have improved and prognosis is getting better, but there is a continuing need for treatment, as lesions regrow when the drug is discontinued.

Patients with TSC2 mutations tend to have more severe neurological symptoms, more cortical tubers, and more severe renal AML than patients with TSC1 mutations. Patients with de novo mutations have no difference in prognosis from familial cases. Early evaluation of neuropsychiatric symptoms (TAND) and individually tailored treatment and educational support are important for improving long-term functional prognosis.

12. Prevention

Tuberous sclerosis is a genetic disease, and primary prevention (prevention of onset) is currently not possible. However, secondary and tertiary prevention are possible through early detection and management of complications, genetic counseling, and genetic testing.

Genetic counseling is essential for TSC patients and families. With autosomal dominant inheritance, the risk of transmission to a child from an affected parent is 50%. Recognizing that de novo mutations account for 65–70% of the total, TSC1/TSC2 testing is recommended even when the parents are clinically normal. Selection of unaffected embryos is possible by preimplantation genetic diagnosis (PGT-M) or prenatal diagnosis.

Neonatal and infant surveillance: Fetuses or neonates in whom cardiac rhabdomyoma is found immediately begin the TSC surveillance protocol (brain MRI, EEG, skin and ophthalmologic examination). Research (the EPISTOP trial) is under way on the possibility of preventive administration of vigabatrin before infantile spasms occur, and early intervention may improve neurodevelopmental prognosis.

Multi-organ surveillance protocol: In accordance with the International TSC Consensus (2012), brain MRI (every 1–3 years), abdominal MRI (every 1–3 years), chest HRCT (women, age 18 or older), EEG (patients with epilepsy), renal function tests, and skin, ophthalmologic, and dental examinations are performed regularly.

Early neurodevelopmental intervention: The earlier speech therapy, occupational therapy, behavioral therapy, and special education are started, the better the functional prognosis. Regular evaluation using the TAND checklist is recommended.

13. References

  1. Northrup H, Krueger DA; International Tuberous Sclerosis Complex Consensus Group. Tuberous sclerosis complex diagnostic criteria update. Pediatr Neurol. 2013;49(4):243-254. PMID: 24053982
  2. Krueger DA, et al. Everolimus for subependymal giant-cell astrocytomas in tuberous sclerosis. N Engl J Med. 2010;363(19):1801-1811. PMID: 21047224
  3. Franz DN, et al. Efficacy and safety of everolimus for subependymal giant cell astrocytomas associated with tuberous sclerosis complex (EXIST-1). Lancet. 2013;381(9861):125-132. PMID: 23158522
  4. Bissler JJ, et al. Everolimus for angiomyolipoma associated with tuberous sclerosis complex or sporadic lymphangioleiomyomatosis (EXIST-2). Lancet. 2013;381(9869):817-824. PMID: 23312829
  5. French JA, et al. Adjunctive everolimus therapy for treatment-resistant focal-onset seizures associated with tuberous sclerosis (EXIST-3). Lancet. 2016;388(10056):2153-2163. PMID: 27613521
  6. van Slegtenhorst M, et al. Identification of the tuberous sclerosis gene TSC1 on chromosome 9q34. Science. 1997;277(5327):805-808. PMID: 9242607
  7. European Chromosome 16 Tuberous Sclerosis Consortium. Identification and characterization of the tuberous sclerosis gene on chromosome 16. Cell. 1993;75(7):1305-1315. PMID: 8269512
  8. Curatolo P, Moavero R, de Vries PJ. Neurological and neuropsychiatric aspects of tuberous sclerosis complex. Lancet Neurol. 2015;14(7):733-745. PMID: 26067125
  9. Amin S, et al. Causes of mortality in individuals with tuberous sclerosis complex. Dev Med Child Neurol. 2017;59(6):612-617. PMID: 28295295
  10. Dombrowski SM, et al. Tuberous sclerosis complex: pathophysiology and emerging therapies. Pediatr Neurol. 2020;110:1-13. PMID: 32653249